Furthermore, when the peripheral effects of the treatment with the anti-NGF mono-clonal antibody mAb911 were assessed in a mouse model of bone cancer pain in which symptoms that reproduce clinical symptoms correlated with the tumor growth and bone remodeling develop [151], this antibody induced a decrease in spontaneous pain behavior [43]. The gene discussed is NGF; the disease is bone cancer.